Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Atai Beckley N.V.ATAI · Entity 72536 | Director | June 26, 2025 | June 27, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Atai Beckley N.V.
Report date June 26, 2025 · Filed June 27, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $2.25 · Expires 2035-06-26 | Direct | 103,000 |
Reported balance
After 2025-06-26 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-06-26 · Grant · Acquired 103,000 · Balance 103,000 F1: The stock option shall vest on the earlier of the day before the ATAI Life Sciences N.V's next annual meeting or June 26, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock option shall vest on the earlier of the day before the ATAI Life Sciences N.V's next annual meeting or June 26, 2026.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
AtaiBeckley Inc.
Report date September 11, 2026 · Filed September 11, 2026
Section 16 reporting ended · disclosed 2026-09-11. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2026-09-11 transaction · row 1
1 source rowRow 1 · 2026-09-11 · Disposition to issuer · Disposed 4,666 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger dated as of July 15, 2026, by and among AtaiBeckley Inc. (the "Company"), Eli Lilly and Company, an Indiana corporation ("Parent"), and Albali Acquisition Corporation, a Delaware corporation and indirect wholly owned subsidiary of Parent ("Merger Sub"), on September 11, 2026, Merger Sub merged with and into the Company (the "Merger"), with the Company surviving as a wholly owned subsidiary of Parent. F2: At the effective time of the Merger (the "Effective Time"), each share of the Company's common stock, par value $0.01 per share, issued and outstanding immediately prior to the Effective Time, subject to certain exceptions, converted into the right to receive (i) $6.75 per share in cash, without interest, plus (ii) one contingent value right per share (each, a "CVR" and collectively, the "CVRs"), representing the right to receive up to an aggregate of $2.50 in cash per CVR upon achievement, if any, of specified clinical and regulatory milestones, less any applicable tax withholding. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $3.84 · Expires 2032-05-25 | Direct | 0 |
Reported balance
After 2026-09-11 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-09-11 · Disposition to issuer · Disposed 64,000 · Balance 0 F3: At the Effective Time, each outstanding stock option of the Company, subject to certain exceptions, was automatically cancelled and converted into the right to receive (A) an amount in cash (without interest and less applicable tax withholdings) equal to the product of (1) the total number of shares subject to such stock option immediately prior to the Effective Time multiplied by (2) the excess of $6.75 over the applicable exercise price per share under such stock option and (B) one CVR for each share subject to such stock option immediately prior to the Effective Time (without regard to vesting). |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $1.88 · Expires 2033-05-23 | Direct | 0 |
Reported balance
After 2026-09-11 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-09-11 · Disposition to issuer · Disposed 64,000 · Balance 0 F3: At the Effective Time, each outstanding stock option of the Company, subject to certain exceptions, was automatically cancelled and converted into the right to receive (A) an amount in cash (without interest and less applicable tax withholdings) equal to the product of (1) the total number of shares subject to such stock option immediately prior to the Effective Time multiplied by (2) the excess of $6.75 over the applicable exercise price per share under such stock option and (B) one CVR for each share subject to such stock option immediately prior to the Effective Time (without regard to vesting). |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $1.34 · Expires 2034-06-13 | Direct | 0 |
Reported balance
After 2026-09-11 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-09-11 · Disposition to issuer · Disposed 103,000 · Balance 0 F3: At the Effective Time, each outstanding stock option of the Company, subject to certain exceptions, was automatically cancelled and converted into the right to receive (A) an amount in cash (without interest and less applicable tax withholdings) equal to the product of (1) the total number of shares subject to such stock option immediately prior to the Effective Time multiplied by (2) the excess of $6.75 over the applicable exercise price per share under such stock option and (B) one CVR for each share subject to such stock option immediately prior to the Effective Time (without regard to vesting). |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $2.25 · Expires 2035-06-26 | Direct | 0 |
Reported balance
After 2026-09-11 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-09-11 · Disposition to issuer · Disposed 103,000 · Balance 0 F3: At the Effective Time, each outstanding stock option of the Company, subject to certain exceptions, was automatically cancelled and converted into the right to receive (A) an amount in cash (without interest and less applicable tax withholdings) equal to the product of (1) the total number of shares subject to such stock option immediately prior to the Effective Time multiplied by (2) the excess of $6.75 over the applicable exercise price per share under such stock option and (B) one CVR for each share subject to such stock option immediately prior to the Effective Time (without regard to vesting). |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $4.50 · Expires 2036-06-04 | Direct | 0 |
Reported balance
After 2026-09-11 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-09-11 · Disposition to issuer · Disposed 121,968 · Balance 0 F3: At the Effective Time, each outstanding stock option of the Company, subject to certain exceptions, was automatically cancelled and converted into the right to receive (A) an amount in cash (without interest and less applicable tax withholdings) equal to the product of (1) the total number of shares subject to such stock option immediately prior to the Effective Time multiplied by (2) the excess of $6.75 over the applicable exercise price per share under such stock option and (B) one CVR for each share subject to such stock option immediately prior to the Effective Time (without regard to vesting). |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Agreement and Plan of Merger dated as of July 15, 2026, by and among AtaiBeckley Inc. (the "Company"), Eli Lilly and Company, an Indiana corporation ("Parent"), and Albali Acquisition Corporation, a Delaware corporation and indirect wholly owned subsidiary of Parent ("Merger Sub"), on September 11, 2026, Merger Sub merged with and into the Company (the "Merger"), with the Company surviving as a wholly owned subsidiary of Parent.
F2: At the effective time of the Merger (the "Effective Time"), each share of the Company's common stock, par value $0.01 per share, issued and outstanding immediately prior to the Effective Time, subject to certain exceptions, converted into the right to receive (i) $6.75 per share in cash, without interest, plus (ii) one contingent value right per share (each, a "CVR" and collectively, the "CVRs"), representing the right to receive up to an aggregate of $2.50 in cash per CVR upon achievement, if any, of specified clinical and regulatory milestones, less any applicable tax withholding.
F3: At the Effective Time, each outstanding stock option of the Company, subject to certain exceptions, was automatically cancelled and converted into the right to receive (A) an amount in cash (without interest and less applicable tax withholdings) equal to the product of (1) the total number of shares subject to such stock option immediately prior to the Effective Time multiplied by (2) the excess of $6.75 over the applicable exercise price per share under such stock option and (B) one CVR for each share subject to such stock option immediately prior to the Effective Time (without regard to vesting).
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 11, 2026 Filed Sep 11, 2026 21:44 UTC | AtaiBeckley Inc. ATAI · Entity 4289 | Disposition to issuerStock Option · Derivative | 121,968 | Not disclosed Strike: $4.50 | Not disclosed |
DisclosureSEC source: 0001140361-26-036382 · form4.xml · derivative · entry 6 Kalali Amir H · CIK 0001403646 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 121,968 shares Expires 2036-06-04 F3 · price: At the Effective Time, each outstanding stock option of the Company, subject to certain exceptions, was automatically cancelled and converted into the right to receive (A) an amount in cash (without interest and less applicable tax withholdings) equal to the product of (1) the total number of shares subject to such stock option immediately prior to the Effective Time multiplied by (2) the excess of $6.75 over the applicable exercise price per share under such stock option and (B) one CVR for each share subject to such stock option immediately prior to the Effective Time (without regard to vesting). F3 · derivative.exercise_date: At the Effective Time, each outstanding stock option of the Company, subject to certain exceptions, was automatically cancelled and converted into the right to receive (A) an amount in cash (without interest and less applicable tax withholdings) equal to the product of (1) the total number of shares subject to such stock option immediately prior to the Effective Time multiplied by (2) the excess of $6.75 over the applicable exercise price per share under such stock option and (B) one CVR for each share subject to such stock option immediately prior to the Effective Time (without regard to vesting). Read SEC document |
| September 11, 2026 Filed Sep 11, 2026 21:44 UTC | AtaiBeckley Inc. ATAI · Entity 4289 | Disposition to issuerStock Option · Derivative | 103,000 | Not disclosed Strike: $2.25 | Not disclosed |
DisclosureSEC source: 0001140361-26-036382 · form4.xml · derivative · entry 5 Kalali Amir H · CIK 0001403646 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 103,000 shares Expires 2035-06-26 F3 · price: At the Effective Time, each outstanding stock option of the Company, subject to certain exceptions, was automatically cancelled and converted into the right to receive (A) an amount in cash (without interest and less applicable tax withholdings) equal to the product of (1) the total number of shares subject to such stock option immediately prior to the Effective Time multiplied by (2) the excess of $6.75 over the applicable exercise price per share under such stock option and (B) one CVR for each share subject to such stock option immediately prior to the Effective Time (without regard to vesting). F3 · derivative.exercise_date: At the Effective Time, each outstanding stock option of the Company, subject to certain exceptions, was automatically cancelled and converted into the right to receive (A) an amount in cash (without interest and less applicable tax withholdings) equal to the product of (1) the total number of shares subject to such stock option immediately prior to the Effective Time multiplied by (2) the excess of $6.75 over the applicable exercise price per share under such stock option and (B) one CVR for each share subject to such stock option immediately prior to the Effective Time (without regard to vesting). Read SEC document |
| September 11, 2026 Filed Sep 11, 2026 21:44 UTC | AtaiBeckley Inc. ATAI · Entity 4289 | Disposition to issuerStock Option · Derivative | 103,000 | Not disclosed Strike: $1.34 | Not disclosed |
DisclosureSEC source: 0001140361-26-036382 · form4.xml · derivative · entry 4 Kalali Amir H · CIK 0001403646 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 103,000 shares Expires 2034-06-13 F3 · price: At the Effective Time, each outstanding stock option of the Company, subject to certain exceptions, was automatically cancelled and converted into the right to receive (A) an amount in cash (without interest and less applicable tax withholdings) equal to the product of (1) the total number of shares subject to such stock option immediately prior to the Effective Time multiplied by (2) the excess of $6.75 over the applicable exercise price per share under such stock option and (B) one CVR for each share subject to such stock option immediately prior to the Effective Time (without regard to vesting). F3 · derivative.exercise_date: At the Effective Time, each outstanding stock option of the Company, subject to certain exceptions, was automatically cancelled and converted into the right to receive (A) an amount in cash (without interest and less applicable tax withholdings) equal to the product of (1) the total number of shares subject to such stock option immediately prior to the Effective Time multiplied by (2) the excess of $6.75 over the applicable exercise price per share under such stock option and (B) one CVR for each share subject to such stock option immediately prior to the Effective Time (without regard to vesting). Read SEC document |
| September 11, 2026 Filed Sep 11, 2026 21:44 UTC | AtaiBeckley Inc. ATAI · Entity 4289 | Disposition to issuerStock Option · Derivative | 64,000 | Not disclosed Strike: $1.88 | Not disclosed |
DisclosureSEC source: 0001140361-26-036382 · form4.xml · derivative · entry 3 Kalali Amir H · CIK 0001403646 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 64,000 shares Expires 2033-05-23 F3 · price: At the Effective Time, each outstanding stock option of the Company, subject to certain exceptions, was automatically cancelled and converted into the right to receive (A) an amount in cash (without interest and less applicable tax withholdings) equal to the product of (1) the total number of shares subject to such stock option immediately prior to the Effective Time multiplied by (2) the excess of $6.75 over the applicable exercise price per share under such stock option and (B) one CVR for each share subject to such stock option immediately prior to the Effective Time (without regard to vesting). F3 · derivative.exercise_date: At the Effective Time, each outstanding stock option of the Company, subject to certain exceptions, was automatically cancelled and converted into the right to receive (A) an amount in cash (without interest and less applicable tax withholdings) equal to the product of (1) the total number of shares subject to such stock option immediately prior to the Effective Time multiplied by (2) the excess of $6.75 over the applicable exercise price per share under such stock option and (B) one CVR for each share subject to such stock option immediately prior to the Effective Time (without regard to vesting). Read SEC document |
| September 11, 2026 Filed Sep 11, 2026 21:44 UTC | AtaiBeckley Inc. ATAI · Entity 4289 | Disposition to issuerStock Option · Derivative | 64,000 | Not disclosed Strike: $3.84 | Not disclosed |
DisclosureSEC source: 0001140361-26-036382 · form4.xml · derivative · entry 2 Kalali Amir H · CIK 0001403646 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 64,000 shares Expires 2032-05-25 F3 · price: At the Effective Time, each outstanding stock option of the Company, subject to certain exceptions, was automatically cancelled and converted into the right to receive (A) an amount in cash (without interest and less applicable tax withholdings) equal to the product of (1) the total number of shares subject to such stock option immediately prior to the Effective Time multiplied by (2) the excess of $6.75 over the applicable exercise price per share under such stock option and (B) one CVR for each share subject to such stock option immediately prior to the Effective Time (without regard to vesting). F3 · derivative.exercise_date: At the Effective Time, each outstanding stock option of the Company, subject to certain exceptions, was automatically cancelled and converted into the right to receive (A) an amount in cash (without interest and less applicable tax withholdings) equal to the product of (1) the total number of shares subject to such stock option immediately prior to the Effective Time multiplied by (2) the excess of $6.75 over the applicable exercise price per share under such stock option and (B) one CVR for each share subject to such stock option immediately prior to the Effective Time (without regard to vesting). Read SEC document |
| September 11, 2026 Filed Sep 11, 2026 21:44 UTC | AtaiBeckley Inc. ATAI · Entity 4289 | Disposition to issuerCommon Stock | 4,666 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-26-036382 · form4.xml · nonDerivative · entry 1 Kalali Amir H · CIK 0001403646 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · price: Pursuant to the Agreement and Plan of Merger dated as of July 15, 2026, by and among AtaiBeckley Inc. (the "Company"), Eli Lilly and Company, an Indiana corporation ("Parent"), and Albali Acquisition Corporation, a Delaware corporation and indirect wholly owned subsidiary of Parent ("Merger Sub"), on September 11, 2026, Merger Sub merged with and into the Company (the "Merger"), with the Company surviving as a wholly owned subsidiary of Parent. F2 · price: At the effective time of the Merger (the "Effective Time"), each share of the Company's common stock, par value $0.01 per share, issued and outstanding immediately prior to the Effective Time, subject to certain exceptions, converted into the right to receive (i) $6.75 per share in cash, without interest, plus (ii) one contingent value right per share (each, a "CVR" and collectively, the "CVRs"), representing the right to receive up to an aggregate of $2.50 in cash per CVR upon achievement, if any, of specified clinical and regulatory milestones, less any applicable tax withholding. Read SEC document |
| June 04, 2026 Filed Jun 9, 2026 00:00 UTC | AtaiBeckley Inc. ATAI · Entity 4289 | GrantStock Option · Derivative | 121,968 | $0.00 Strike: $4.50 | $0.00 |
DisclosureSEC source: 0001140361-26-024522 · form4.xml · derivative · entry 1 Kalali Amir H · CIK 0001403646 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 121,968 Underlying: Common Stock · 121,968 shares Expires 2036-06-04 F1 · derivative.exercise_date: The stock option shall vest on the earlier of the day before AtaiBeckley Inc.'s next annual meeting or June 4, 2027, subject to continued service on AtaiBeckley Inc.'s board of directors through the applicable vesting date. Read SEC document |
| June 26, 2025 Filed Jun 27, 2025 21:31 UTC | Atai Beckley N.V. ATAI · Entity 72536 | GrantStock Option · Derivative | 103,000 | $0.00 Strike: $2.25 | $0.00 |
DisclosureSEC source: 0001140361-25-024022 · form4.xml · derivative · entry 1 Kalali Amir H · CIK 0001403646 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 103,000 Underlying: Common Shares · 103,000 shares Expires 2035-06-26 F1 · derivative.exercise_date: The stock option shall vest on the earlier of the day before the ATAI Life Sciences N.V's next annual meeting or June 26, 2026. Read SEC document |
| June 13, 2024 Filed Jun 14, 2024 21:00 UTC | Atai Beckley N.V. ATAI · Entity 72536 | GrantStock Option · Derivative | 103,000 | $0.00 Strike: $1.34 | $0.00 |
DisclosureSEC source: 0001140361-24-030205 · form4.xml · derivative · entry 1 Kalali Amir H · CIK 0001403646 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 103,000 Underlying: Common Shares · 103,000 shares Expires 2034-06-13 F1 · derivative.exercise_date: The stock option shall vest on the earlier of the day before the ATAI Life Sciences N.V's next annual meeting or June 13, 2025. Read SEC document |
| May 23, 2023 Filed May 25, 2023 20:15 UTC | Atai Beckley N.V. ATAI · Entity 72536 | GrantStock Option · Derivative | 64,000 | $0.00 Strike: $1.88 | $0.00 |
DisclosureSEC source: 0000950170-23-024241 · ownership.xml · derivative · entry 1 Kalali Amir H · CIK 0001403646 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 64,000 Underlying: Common Shares · 64,000 shares Expires 2033-05-23 F1 · derivative.exercise_date: The stock option shall vest on the earlier of the day before the ATAI Life Sciences N.V's next annual meeting or May 16, 2024. Read SEC document |
| May 25, 2022 Filed May 27, 2022 21:50 UTC | Atai Beckley N.V. ATAI · Entity 72536 | GrantStock Option · Derivative | 64,000 | $0.00 Strike: $3.84 | $0.00 |
DisclosureSEC source: 0000899243-22-019970 · doc4.xml · derivative · entry 1 Kalali Amir H · CIK 0001403646 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,000 Underlying: Common Shares · 64,000 shares Expires 2032-05-25 F1 · derivative.exercise_date: The stock option shall vest on the earlier of the day before ATAI Life Sciences N.V.'s next annual meeting or May 25, 2023. Read SEC document |
| September 10, 2021 Filed Sep 13, 2021 20:31 UTC | Atai Beckley N.V. ATAI · Entity 72536 | GrantStock Option · Derivative | 128,000 | $0.00 Strike: $16.46 | $0.00 |
DisclosureSEC source: 0000899243-21-035682 · doc4.xml · derivative · entry 1 Kalali Amir H · CIK 0001403646 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 128,000 Underlying: Common Shares · 128,000 shares Expires 2031-09-10 F1 · derivative.exercise_date: The stock option shall vest with respect to a third of the underlying common shares on June 17, 2022 and in 24 substantially equal monthly installments thereafter until June 17, 2024. Read SEC document |
| June 22, 2021 Filed Jun 24, 2021 20:16 UTC | Atai Beckley N.V. ATAI · Entity 72536 | PurchaseCommon Shares | 4,666 | $15.00 | $69,990.00 |
DisclosureSEC source: 0000899243-21-025740 · doc4.xml · nonDerivative · entry 1 Kalali Amir H · CIK 0001403646 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,666 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.